dopamine agonists And NotNadeeka N. W. Dissanayaka
List of bibliographic references
Number of relevant bibliographic references: 31.Ident. | Authors (with country if any) | Title |
---|---|---|
000136 | Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease |
000137 | Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease |
000197 | Atbin Djamshidian [Royaume-Uni] ; Francisco Cardoso [Brésil] ; Donald Grosset [Royaume-Uni] ; Henrietta Bowden-Jones [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Pathological gambling in Parkinson's disease—a review of the literature |
000254 | Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's disease therapeutics |
000280 | Maria Milenkova [Allemagne, Bulgarie] ; Bahram Mohammadi [Allemagne] ; Katja Kollewe [Allemagne] ; Christoph Schrader [Allemagne] ; Anja Fellbrich [Allemagne] ; Matthias Wittfoth [Allemagne] ; Reinhard Dengler [Allemagne] ; Thomas F. Münte [Allemagne] | Intertemporal choice in Parkinson's disease |
000284 | Maria Papathanou [Suède] ; Sarah Rose [Royaume-Uni] ; Andrew Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats |
000333 | Olivier Rascol [France] | Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release |
000681 | Sean S. O'Sullivan [Royaume-Uni] ; Atbin Djamshidian [Royaume-Uni, Autriche] ; Zeshan Ahmed [Royaume-Uni] ; Andrew H. Evans [Australie] ; Andrew D. Lawrence [Royaume-Uni] ; Janice L. Holton [Royaume-Uni] ; Tamas Revesz [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Impulsive‐compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy |
000970 | Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie] | Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long‐term observation |
000B48 | Frank Andersohn [Allemagne] ; Edeltraut Garbe [Allemagne] | Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists |
000B50 | Louis C. S. Tan [Singapour] ; Kenneth K. C. Ng [Singapour] ; Wing-Lok Au [Singapour] ; Raymond K. K. Lee [Singapour] ; Yiong-Huak Chan [Singapour] ; Nigel C. K. Tan [Singapour] | Bromocriptine use and the risk of valvular heart disease |
000C36 | Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis] | Treatment of levodopa‐induced motor complications |
000C96 | A. H. V. Schapira [Royaume-Uni] | Progress in neuroprotection in Parkinson’s disease |
000C98 | Peter Jenner [Royaume-Uni] | Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities |
000D72 | Shen-Yang Lim [Canada] ; Andrew H. Evans [Australie] ; Janis M. Miyasaki [Canada] | Impulse Control and Related Disorders in Parkinson's Disease |
000F33 | Charlene Hoffman Snyder [États-Unis] ; Charles H. Adler [États-Unis] | The patient with Parkinson’s disease: Part I–Treating the motor symptoms;Part II–Treating the nonmotor symptoms |
001035 | Claudio Lucetti [Italie] ; Paulo Del Dotto [Italie] ; Gianna Gambaccini [Italie] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Caterina Berti [Italie] ; Giuseppe Rossi [Italie] ; Maria Cristina Bianchi [Italie] ; Michela Tosetti [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie] | Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study |
001050 | Anthony H. V. Schapira [Royaume-Uni] | Future directions in the treatment of Parkinson's disease |
001185 | Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
001315 | Daniel Oved [Israël] ; Ilan Ziv [Israël] ; Therese A. Treves [Israël] ; Diana Paleacu [Israël] ; Eldad Melamed [Israël] ; Ruth Djaldetti [Israël] | Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease |
001318 | C. Vossius [Norvège] ; M. Gjerstad [Norvège] ; H. Baas [Allemagne] ; J. P. Larsen [Norvège] | Drug costs for patients with Parkinson's disease in two different European countries |
001442 | A H V. Schapira | Present and future drug treatment for Parkinson’s disease |
001498 | Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
001584 | Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada] | Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations |
001607 | Padraig E. O'Suilleabhain [États-Unis] ; Teodoro Bottiglieri [États-Unis] ; Richard B. Dewey Jr. [États-Unis] ; Shailja Sharma [États-Unis] ; Ramon Diaz-Arrastia [États-Unis] | Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease |
001709 | Matthew A. Brodsky [États-Unis] ; James Godbold [États-Unis] ; Tom Roth [États-Unis] ; C. Warren Olanow [États-Unis] | Sleepiness in Parkinson's disease: A controlled study |
001710 | Sebastian Paus [Allemagne] ; Hans Michael Brecht [Allemagne] ; Jürgen Köster [Allemagne] ; Gert Seeger [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease |
001750 | Birgit Högl [Autriche] ; Klaus Seppi [Autriche] ; Elisabeth Brandauer [Autriche] ; Susanne Glatzl [Autriche] ; Birgit Frauscher [Autriche] ; Ulrike Niedermüller [Autriche] ; Gregor Wenning [Autriche] ; Werner Poewe [Autriche] | Increased daytime sleepiness in Parkinson's disease: A questionnaire survey |
001784 | A. Albanese [Italie] ; C. Colosimo [Italie] | Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists |
001C62 | B. Bergamasco ; L. Frattola ; A. Muratorio ; F. Piccoli ; F. Mailland ; L. Parnetti | Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study |
001D61 | Martin Goulet ; Marc Morissette ; Richard Grondin ; Pierre Falardeau ; Paul J. Bédard ; William Rostène [France] ; Thérèse Di Paolo | Neurotensin receptors and dopamine transporters: Effects of MPTP lesioning and chronic dopaminergic treatments in monkeys |
This area was generated with Dilib version V0.6.23. |